Great article and assessment Dr. Fung. My co-author Stephen Ponder MD FAAP CDE and I are working on an article addressing the current business dynamics as they relate to type 1 diabetes including the effects of perceived commoditization on patient access to necessary tools including insulin, devices and education. This trend toward controlled access through pharmacy benefit managers is also poised to stifle innovation and thus prop up those companies who already have contracts for their old technology vs those who are working on improvements and would be competitors.
Sadly, it is a game to these people at the top. Your advice to ‘follow the money’ is all too true.